C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Top Cited Papers
Open Access
- 15 April 2009
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 301 (15) , 1573-1579
- https://doi.org/10.1001/jama.2009.470
Abstract
Accumulated clinical experience indicates that there is an inverse association between beta-cell function and chronic complications of type 1 diabetes mellitus (DM)—the higher the C-peptide levels (an indirect measure of viable beta-cell function), the lower the incidence of microvascular complications of type 1 DM.1 Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees.2,3Keywords
This publication has 9 references indexed in Scilit:
- Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell ModulationDiabetes, 2009
- Faculty Opinions recommendation of Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.Published by H1 Connect ,2007
- Translational Mini-Review Series on Type 1 Diabetes: Immune-based therapeutic approaches for type 1 diabetesClinical and Experimental Immunology, 2007
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2006
- Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral dosesClinical Pharmacology & Therapeutics, 2005
- Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2005
- Autoimmune thyroid dysfunction after hematopoietic stem cell transplantationBone Marrow Transplantation, 2005
- Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications TrialAnnals of Internal Medicine, 1998